



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/965,796

10/01/2001

David M. Goldenberg

IMMU:007US3

3640

37013 7590 09/09/2009  
ROSSI, KIMMS & McDOWELL LLP.  
20609 Gordon Park Square, Suite 150  
Ashburn, VA 20147

EXAMINER

HARRIS, ALANA M

ART UNIT

PAPER NUMBER

1643

MAIL DATE

DELIVERY MODE

09/09/2009

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
09965796	10/1/01	GOLDENBERG, DAVID M.	IMMU:007US3

ROSSI, KIMMS & McDOWELL LLP.  
20609 Gordon Park Square, Suite 150  
Ashburn, VA 20147

**EXAMINER**

Alana M.. Harris, Ph.D.

ART UNIT	PAPER
1643	20090905

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

Application No: 09/965,796

In response to the Undocketed Appeal returned to the Examiner:

The Examiner has obtained a copy of the missing non-patent literature (NPL), Maloney, D.G. et al. "Phase I Critical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma" Blood 84(8)L 2457-2466, October 15, 1994) that was submitted as reference A11 by Appellants on Form PTO-1449 October 1, 2001 and reviewed by said Examiner January 6, 2004.

The application has been forwarded to the Board of Patent Appeals and Interferences for decision on the appeal.

/Alana M. Harris, Ph.D./  
Primary Examiner, Art Unit 1643